PYC Therapeutics (ASX:PYC)
ASX announcement history & article coverage
Transparent by design.
Announcments by PYC Therapeutics (ASX:PYC) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Exercise of Options and Cleansing Notice
Notice of Annual General Meeting/Proxy Form
Application for quotation of securities - PYC
Notification of cessation of securities - PYC
PKD Program - Presentation of Data at ASN Conference
PYC reports exploratory biomarker gains for PYC-003 PKD therapy ahead of ASN presentation
RP11 PROGRAM - PRESENTATION AT EURETINA 2026
PKD - First Patient Dosed in OLE Study
Investor Webinar Presentation Q3 2026
ADOA Program - Data Presentation
Ceasing to be a substantial holder
PKD - Presentation of Clinical Safety Data
2026 Corporate Governance Statement
Appendix 4G
2026 Annual Report to Shareholders
PYC Therapeutics advances RNA drug pipeline with $600M capital raise and clinical progress in FY2026
Appendix 4E
Notification regarding unquoted securities - PYC
Investor Webinar
Change of Director's Interest Notice
Notification regarding unquoted securities - PYC
Quarterly Activities/Appendix 4C Cash Flow Report
PYC Therapeutics advances RNA drug candidates in clinical trials with strong cash position
PKD - Safety Committee Approves Dose Escalation
PYC Therapeutics gets approval for dose escalation and extension in Phase 1b PKD study
ADOA Program Update
PYC Therapeutics reports sustained efficacy and safety of PYC-001 in ADOA with potential extended dosing interval
Notification of cessation of securities - PYC
Presentation At 2026 PMS Foundation Family Conference